Bottle Single Use DISINFECTANT, HYDE OUT ALDEHYDE NUTRL (12/CS) Features Neutralizes glutaraldehyde and OPA high level disinfectant/sterilant solutions and converts the solutions into non-toxic, non-hazardous waste Once neutralized, solutions may be safely washed down the drain Fast acting - 5 minutes to complete neutralization More Log in for pricing and availability Log In to Order or Product Specifications Features Neutralizes glutaraldehyde and OPA high level disinfectant/sterilant solutions and converts the solutions into non-toxic, non-hazardous waste Once neutralized, solutions may be safely washed down the drain Fast acting - 5 minutes to complete neutralization Each bottle neutralizes up to 2 gallons of glutaraldehyde or 16 gallons of OPA No mess dispensing with tip-and-pour bottle Glycine based More Information Related Products ,for, Item ID- #927271 Cetylite #0122 Frequently Viewed Together ,for, Item ID- #852217 McKesson Brand #73-OPA28 ,for, Item ID- #862477 McKesson Brand #341 ,for, Item ID- #862479 McKesson Brand #344 ,for, Item ID- #239933 Pfizer #00409397703 ,for, Item ID- #852479 Urgo Medical North America LLC #00312 ,for, Item ID- #852480 Urgo Medical North America LLC #00314 ,for, Item ID- #157452 Metrex Research #10-2800 ,for, Item ID- #636937 Metrex Research #10-6000 ,for, Item ID- #157453 Metrex Research #10-2805 ,for, Item ID- #738857 Bravida Medical #4008TC ,for, Item ID- #546167 Medical Chemical #0104-1GL ,for, Item ID- #823593 Civco Medical Instruments #610-1045 ,for, Item ID- #684173 Smith & Nephew #59449200 ,for, Item ID- #626431 Abbott Nutrition #57801 ,for, Item ID- #1211710 Geri-Care #Q451-08-GCP ,for, Item ID- #326722 Smith & Nephew #449000
Her National Cancer Institute website gives further details
blshaw October 1, 2023, 9:37am 2 rusty_hammer: Any and all comments welcome
These may include temporary dizziness, mild headache resolving within hours, slight fatigue (usually with higher doses), and occasional mild nausea
Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
